The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
The company announced positive topline data from the Phase II ZUPREME-1 trial
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Subscribe To Our Newsletter & Stay Updated
